Rapid Dose Therapeutics Corp. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Rapid Dose Therapeutics Corp.

Avicanna, Inc.

Microbix Biosystems, Inc.

Ceapro, Inc.

Oncolytics Biotech, Inc.

Cardiol Therapeutics, Inc.

FSD Pharma, Inc.

Medicenna Therapeutics Corp.

Sernova Corp.

BriaCell Therapeutics Corp.

Cognetivity Neurosciences Ltd.

Why is Rapid Dose Therapeutics Corp. ?

Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months

Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -0.72

The company has declared Negative results for the last 4 consecutive quarters

INTEREST(HY) At CAD 0.59 MM has Grown at 113.06%
OPERATING CASH FLOW(Y) Lowest at CAD -2.44 MM
NET PROFIT(HY) At CAD -2.46 MM has Grown at -43.95%

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -2.86%, its profits have fallen by -101.4%

Underperformed the market in the last 1 year

Even though the market (S&P/TSX 60) has generated returns of 21.04% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -2.86% returns

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Rapid Dose Therapeutics Corp. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Rapid Dose Therapeutics Corp.

-40.74%

-0.20

111.50%

S&P/TSX 60

19.1%

1.43

14.72%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-78.88%

EBIT Growth (5y)

-164.79%

EBIT to Interest (avg)

-0.73

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.50

Sales to Capital Employed (avg)

-2,127.70

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

6,711.89%

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-3.98

EV to EBIT

-6.50

EV to EBITDA

-7.05

EV to Capital Employed

-10.39

EV to Sales

9.80

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

17What is working for the Company

NET SALES(HY)

At CAD 1.45 MM has Grown at 145.3%

RAW MATERIAL COST(Y)

Fallen by -80.98% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -99.71 %

DEBTORS TURNOVER RATIO(HY)

Highest at 11.3%

OPERATING PROFIT(Q)

Highest at CAD -0.37 MM

PRE-TAX PROFIT(Q)

Highest at CAD -0.72 MM

NET PROFIT(Q)

Highest at CAD -0.72 MM

EPS(Q)

Highest at CAD -0.01

-3What is not working for the Company

INTEREST(9M)

At CAD 0.91 MM has Grown at 27.3%

Here's what is working for Rapid Dose Therapeutics Corp.

Net Sales

At CAD 1.45 MM has Grown at 145.3%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very positive

Net Sales (CAD MM)

Operating Profit

Highest at CAD -0.37 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (CAD MM)

Pre-Tax Profit

Highest at CAD -0.72 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CAD MM)

Net Profit

Highest at CAD -0.72 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CAD MM)

EPS

Highest at CAD -0.01

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CAD)

Debt-Equity Ratio

Lowest at -99.71 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Debtors Turnover Ratio

Highest at 11.3%

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -80.98% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Rapid Dose Therapeutics Corp.

Interest

At CAD 0.91 MM has Grown at 27.3%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CAD MM)